The effect of dioxidovanadium complex (V) on hepatic function in streptozotocin-induced diabetic rats.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Canadian Science Publishing Country of Publication: Canada NLM ID: 0372712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1205-7541 (Electronic) Linking ISSN: 00084212 NLM ISO Abbreviation: Can J Physiol Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: 2011- : Ottawa, ON : Canadian Science Publishing
      Original Publication: Ottawa, National Research Council of Canada.
    • Subject Terms:
      Coordination Complexes/*pharmacology ; Diabetes Mellitus, Experimental/*physiopathology ; Liver/*drug effects ; Liver/*physiopathology ; Vanadium/*chemistry; Animals ; Blood Glucose/metabolism ; Body Weight/drug effects ; C-Reactive Protein/metabolism ; Coordination Complexes/therapeutic use ; Diabetes Mellitus, Experimental/blood ; Diabetes Mellitus, Experimental/drug therapy ; Diabetes Mellitus, Experimental/pathology ; Lipids/blood ; Liver/pathology ; Male ; Organ Size/drug effects ; Oxidative Stress/drug effects ; Rats ; Rats, Sprague-Dawley
    • Abstract:
      Diabetics are susceptible to hepatic dysfunction risks due to hyperglycaemia and insulin therapy. Conventional diabetes treatments improve glycaemic control; however, hepatic hazards associated with these agents remains a challenge. Accordingly, this study sought to investigate the effect of a dioxidovanadium complex (V) on the hepatic function in streptozotocin-induced diabetic rats. Sprague-Dawley rats (240-250 g) were divided into 4 groups ( n = 6): nondiabetic control, diabetic control, insulin-treated, and vanadium complex groups. The dioxidovanadium (10, 20, and 40 mg/kg) was administered twice every 2nd day for 5 weeks and blood glucose concentration was monitored weekly. At the end of the experimental period, all the experimental groups were sacrificed, and then the lipid profile, liver superoxide dismutase, glutathione peroxidase and malondialdehyde, plasma alanine aminotransferase and aspartate aminotransferase, and C-reactive protein (CRP) concentration were measured. The administration of dioxidovanadium significantly alleviated hyperglycaemia with concomitant attenuation in oxidative stress as evidenced by reduced malondialdehyde concentrations. Furthermore, vanadium complex abolished diabetes-induced dyslipidaemia. Lastly, vanadium complex administration attenuated the increase in alanine aminotransferase, aspartate aminotransferase, and plasma C-reactive protein. These findings suggest that this metallo-compound (dioxidovanadium) may ameliorate liver dysfunction often observed in diabetes.
    • Contributed Indexing:
      Keywords: C-reactive protein; dysfonctionnement hépatique; hyperglycaemia; hyperglycémie; liver dysfunction; liver function marker enzymes; marqueurs enzymatiques du fonctionnement hépatique; oxidative stress; protéine C réactive; stress oxydatif
    • Accession Number:
      0 (Blood Glucose)
      0 (Coordination Complexes)
      0 (Lipids)
      00J9J9XKDE (Vanadium)
      9007-41-4 (C-Reactive Protein)
    • Publication Date:
      Date Created: 20190907 Date Completed: 20200330 Latest Revision: 20200330
    • Publication Date:
      20240829
    • Accession Number:
      10.1139/cjpp-2019-0369
    • Accession Number:
      31491333